Cancer Immunology Reserch

Cancer Immunol Res. 2024 Oct 8. doi: 10.1158/2326-6066.CIR-23-0639. Online ahead of print. ABSTRACT Neoantigen-targeted therapy holds an array of benefits for cancer immunotherapy, but the identification of peptide targets with tumor rejection capacity remains a limitation. To better define the criteria dictating tumor rejection potential, we examined the capacity of high-magnitude T cell responses induced … Read more

Cancer Immunol Res. 2024 Oct 4. doi: 10.1158/2326-6066.CIR-24-0089. Online ahead of print. ABSTRACT The histone methyltransferase enhancer of zeste homolog 2 (EZH2) plays important roles in T-cell differentiation, proliferation and function. Previous studies have demonstrated that genetic deletion of EZH2 in CD8+ or total T cells impairs their antiviral and antitumor activity, cytokine production and … Read more

Cancer Immunol Res. 2024 Oct 1;12(10):1309. doi: 10.1158/2326-6066.CIR-12-10-WWR. NO ABSTRACT PMID:39350684 | DOI:10.1158/2326-6066.CIR-12-10-WWR

Cancer Immunol Res. 2024 Sep 30. doi: 10.1158/2326-6066.CIR-23-1027. Online ahead of print. ABSTRACT Ovarian cancers and microsatellite stable (MSS) colorectal cancers (CRC) are insensitive to anti-PD1 immunotherapy, and new immunotherapeutic approaches are needed. Preclinical data suggests a relationship between immunotherapy resistance and elevated angiopoietin 2 levels. We performed a phase 1 dose-escalation study of pembrolizumab … Read more

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-24-0026. Online ahead of print. ABSTRACT Radiotherapy (RT) triggers an immune response that contributes to anti-tumor effects. Induction of interferon beta (IFN-β) is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFN-β expression in Toll-like receptor-activated myeloid cells. … Read more

Cancer Immunol Res. 2024 Sep 26. doi: 10.1158/2326-6066.CIR-23-1075. Online ahead of print. ABSTRACT Despite recent advances in immunotherapy with immune checkpoint inhibitors (ICI), many patients with non-small cell lung cancer (NSCLC) fail to respond or develop resistance after an initial response. In situ vaccination (ISV) with engineered viruses has emerged as a promising antigen-agnostic strategy … Read more

Cancer Immunol Res. 2024 Sep 20. doi: 10.1158/2326-6066.CIR-23-0868. Online ahead of print. ABSTRACT Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Butyrophilin subfamily 2 member A1 (BTN2A1) is a surface protein that has recently been shown to bind the Vγ9 chain of the γδ T-cell receptor (TCR) but its precise role in modulating Vγ9Vδ2 … Read more

Cancer Immunol Res. 2024 Sep 16. doi: 10.1158/2326-6066.CIR-24-0037. Online ahead of print. ABSTRACT T cells expressing PD-1 in the peripheral blood (PB) of patients with tumors possess therapeutic potential; however, the immunosuppressive, PD1-triggered signaling pathway and limited proliferative capacity of PD-1+ T cells present challenges to their therapeutic application. Here, we observed no discernible distinction … Read more

Cancer Immunol Res. 2024 Sep 13:OF1-OF9. doi: 10.1158/2326-6066.CIR-23-0642. Online ahead of print. ABSTRACT Neutrophils are the primary myeloid cells that are recruited to inflamed tissues, and they are key players during colitis, being also present within the tumor microenvironment during the initiation and growth of colon cancer. Neutrophils fundamentally serve to protect the host against … Read more

Cancer Immunol Res. 2024 Sep 13. doi: 10.1158/2326-6066.CIR-24-0469. Online ahead of print. ABSTRACT Accumulating evidence indicates that the gut microbiome influences cancer progression and therapy. We recently showed that progressive changes in gut microbial diversity and composition are closely associated with tobacco-associated lung adenocarcinoma (LUAD) in a human-relevant mouse model. Furthermore, we demonstrated that the … Read more